期刊
MOLECULAR AND CELLULAR BIOLOGY
卷 40, 期 2, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1128/MCB.00307-19
关键词
ALDH1A1; SOX9; cancer stem-like cells; chemoresistance
资金
- National Institutes of Health [S10OD016165, R01ES022968, R01-EB018857, P20RR016440, P20GM103434, P30RR032138/P30GM103488]
- WVU Cancer Institute
- Institutional Development Awards (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM103434, P30GM103488]
Chemotherapy resistance and tumor relapse are the major contributors to low patient survival, and both have been largely attributed to cancer stem-like cells (CSCs) or tumor-initiating cells (TlCs). Moreover, most conventional therapies are not effective against CSCs, which necessitates the discovery of CSC-specific biomarkers and drug targets. Here, we demonstrated that the embryonic transcription factor SOX9 is an important regulator of acquired chemoresistance in non-small-cell lung cancer (NSCLC). Our results show that SOX9 expression is elevated in NSCLC cells after treatment with the chemotherapeutic cisplatin and that overexpression of SOX9 correlates with worse overall survival in lung cancer patients. We further demonstrated that SOX9 knockdown increases cellular sensitivity to cisplatin, whereas its overexpression promotes drug resistance. Moreover, this transcription factor promotes the stem-like properties of NSCLC cells and increases their aldehyde dehydrogenase (ALDH) activity, which was identified to be the key mechanism of SOX9-induced chemoresistance. Finally, we showed that ALDH1A1 is a direct transcriptional target of SOX9, based on chromatin immunoprecipitation and luciferase reporter assays. Taken together, our novel findings on the role of the SOX9-ALDH axis support the use of this CSC regulator as a prognostic marker of cancer chemoresistance and as a potential drug target for CSC therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据